ProQR Therapeutics N.V. - Ordinary Shares (PRQR) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$1.77
Trend Context
Mixed / range
Latest briefing
What's happening with PRQR
seekingalpha.com4 Jul 2026
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data. PRQR differentiates itself by prioritizing NTCP modulation in rare pediatric liver disease (biliary atresia), aiming for a faster, cleaner clinical validation path than competitors. Recent financings, including a $50M direct offering and Eli Lilly's $9.2M investment, extend PRQR's cash runway to mid-2027, supporting multip…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com25 Jun 2026
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximat…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com12 May 2026
ProQR Announces First Quarter 2026 Operating and Financial Results
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
11 May 2026
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
